GLP-1 Myth or Fact? 12 Everyday Claims, Sorted

Myth. The Wegovy and Zepbound labels both say the weekly injection can be taken at any time of day, with or without meals. What matters is sticking to the same day each week. If you miss a dose, follow the missed-dose rules on your label.

Myth. And the pills don't all share one set of rules either. The Wegovy tablet is taken once a day on an empty stomach with no more than 4 ounces of plain water, swallowed whole, and then you wait at least 30 minutes before eating, drinking or taking other oral medicines. Foundayo (orforglipron), approved in April 2026, is taken once daily with or without food. Same goal, very different mornings.

Fact. A 2025 joint advisory from four nutrition and obesity medicine societies notes that vomiting is more likely after large meals. It suggests smaller meals and avoiding large or high-fat meals when diarrhea is a problem. It also suggests going easy on alcohol, which can worsen nausea and reflux. Not a ban list, just a pattern worth knowing.

Myth. Eating less is exactly why protein matters. The same advisory lists adequate protein plus strength training as a priority to help preserve lean mass. It notes that targets of 1.2–1.6 g per kg of body weight per day have been proposed during active weight loss, and it mentions 80–120 g a day as an alternative absolute target. Your own number depends on your health, so ask your clinician or a dietitian.

Myth. In the adult Wegovy trials, 44% of people on the medicine reported nausea, compared with 16% on placebo. Flip that around: more than half of people on Wegovy didn't report nausea at all, and the trials still showed clear average weight loss. More in do GLP-1 medicines need side effects to work?

Fact, for the big injectables. On the Wegovy label, nausea (44%) tops the list, ahead of diarrhea (30%), vomiting (24%) and constipation (24%). On the Zepbound label, nausea ran from 25% to 29% across doses, versus 8% on placebo. Rates differ by drug and dose, so your own label is the one to check.

Myth. The Zepbound label tells people on oral hormonal contraceptives to switch to a non-oral method or add a barrier method for 4 weeks after starting and after each dose increase. The Foundayo label has similar advice for 30 days after starting and after each increase. Not every GLP-1 label says this, which is the point: ask your prescriber or pharmacist about yours. Details in tirzepatide and the pill.

Myth. The Wegovy label says semaglutide lowers body weight "with greater fat mass loss than lean mass loss." Lean mass does drop too, which is why the advisory pairs protein with strength training. "Some" isn't "all." Read more in hair loss and muscle loss on GLP-1s.

Myth. In the 68-week trial on the Wegovy label, the average was −14.9% (vs −2.4% on placebo). But only 47.9% of people on the medicine reached 15% or more. 83.5% lost at least 5%, which means about 1 in 6 didn't reach even that. Averages describe a group, not a person.

Needs context, leaning myth. In the STEP 1 extension, people who stopped semaglutide had regained about two-thirds of their lost weight a year later. They still ended about 5.6% below their starting weight on average. That's an average from 327 people in an exploratory analysis, so individual results vary. It's a planning conversation to have with your prescriber, not a reason to panic. See what happens when you stop semaglutide.

Myth, as of 2026. The current DailyMed label for oral semaglutide covers both Rybelsus and Ozempic tablets, for adults with type 2 diabetes. The label notes the two tablets are not interchangeable milligram for milligram. Brand names are getting complicated, so read the box, not the nickname.

Myth. Very rare means unlikely, not irrelevant. In 2025 the European Medicines Agency listed NAION, an eye condition that can cause sudden vision loss, as a very rare side effect of semaglutide, affecting up to 1 in 10,000 people. The useful takeaway is the warning sign: contact a doctor promptly if your vision suddenly drops or gets worse fast.